Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941

This study has been completed.
Information provided by:
Astellas Pharma Inc Identifier:
First received: February 1, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
This study determined the safety of ASP1941 after a single and multiple once-daily doses for 10 days in healthy subjects. In addition, the Pharmacokinetics (PK) and Pharmacodynamics (PD) of ASP1941 were assessed.

Condition Intervention Phase
Drug: ASP1941
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of ASP1941 and to Explore the Effect of ASP1941 on Urine and Blood Glucose Levels in Healthy Subjects

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests [ Time Frame: 31 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pharmacokinetics assessed by the ASP1941 plasma concentration change [ Time Frame: up to 96 hours after last dose ] [ Designated as safety issue: No ]
  • Pharmacodynamics assessed by the ASP1941 glucose concentration changes in blood and urine [ Time Frame: up to 96 hours after last dose ] [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: May 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ASP1941
    Drug: Placebo

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body weight between 60-100kg, body mass index (BMI) between 20-30 kg/m2, inclusive

Exclusion Criteria:

  • Fasting Plasma Glucose (FPG) > 6.4 mmol/l
  • HbA1c > 6.2%
  • Abnormal pulse of blood pressure at screening, as judged by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01288898

Groningen, Netherlands, 9470 AE
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Use Central Contact Astellas Pharma Europe B.V.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Disclosure Office Europe, Astellas Pharma Europe BV Identifier: NCT01288898     History of Changes
Other Study ID Numbers: 1941-CL-0002  2006-006525-11 
Study First Received: February 1, 2011
Last Updated: February 1, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Astellas Pharma Inc:
Diabetes Mellitus
Multiple ascending doses
Healthy subjects processed this record on May 22, 2016